Elena Massarotti
YOU?
Author Swipe
View article: Clonally expanded CD38 <sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Clonally expanded CD38 <sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis Open
Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spont…
View article: Granzyme K <sup>+</sup> CD8 T cells form a core population in inflamed human tissue
Granzyme K <sup>+</sup> CD8 T cells form a core population in inflamed human tissue Open
T cell–derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. Although these cytokines have traditionally been attributed to CD4 T cells, we have found that CD8 T cells are notably abundant in syno…
View article: SLAMF7 engagement superactivates macrophages in acute and chronic inflammation
SLAMF7 engagement superactivates macrophages in acute and chronic inflammation Open
Macrophages regulate protective immune responses to infectious microbes, but aberrant macrophage activation frequently drives pathological inflammation. To identify regulators of vigorous macrophage activation, we analyzed RNA-seq data fro…
View article: Clonally expanded CD38<sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis
Clonally expanded CD38<sup>hi</sup> cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis Open
Immune checkpoint inhibitor (ICI) therapies that promote T cell activation have improved outcomes for advanced malignancies yet also elicit harmful autoimmune reactions. The T cell mechanisms mediating these iatrogenic autoimmune events re…
View article: Trends in the Incidence, Demographics and Outcomes of End-Stage Renal Disease Due to Lupus Nephritis in the U.S., 1995–2006
Trends in the Incidence, Demographics and Outcomes of End-Stage Renal Disease Due to Lupus Nephritis in the U.S., 1995–2006 Open
It is unknown whether recent advances lupus nephritis (LN) treatment have led to changes in the incidence of end-stage renal disease (ESRD) secondary to LN, or in the characteristics, therapies, and outcomes of patients with LN ESRD.
View article: Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus
Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Open
Background Systemic lupus erythematosus (SLE) is a systemic autoimmune inflammatory disorder associated with premature atherosclerosis and increased cardiovascular risk. Systemic inflammation is an emerging risk factor for coronary microva…
View article: A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus Open
Objective To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumato…
View article: Cell-bound complement activation products associate with lupus severity in SLE
Cell-bound complement activation products associate with lupus severity in SLE Open
Objectives To evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4. Methods All subjects (n=495) fulfilled the American College of Rheumatology (ACR) c…
View article: Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE Open
Objective We compared the physician-assessed diagnostic likelihood of SLE resulting from standard diagnosis laboratory testing (SDLT) to that resulting from multianalyte assay panel (MAP) with cell-bound complement activation products (MAP…
View article: Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus Open
Objective To evaluate the frequency of cell‐bound complement activation products ( CB ‐ CAP s) as a marker of complement activation in patients with suspected systemic lupus erythematosus ( SLE ) and the usefulness of this biomarker as a p…
View article: 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus Open
Objective To develop new classification criteria for systemic lupus erythematosus ( SLE ) jointly supported by the European League Against Rheumatism ( EULAR ) and the American College of Rheumatology ( ACR ). Methods This international in…
View article: The immune cell landscape in kidneys of patients with lupus nephritis
The immune cell landscape in kidneys of patients with lupus nephritis Open
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients with lupus nephritis and from …
View article: Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer
Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer Open
Safe use of immune checkpoint blockade in patients with cancer and autoimmune disorders requires a better understanding of the pathophysiology of immunologic activation. We describe the immune correlates of reactivation of granulomatosis w…
View article: Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings
Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings Open
Navigators uncovered and addressed a number of medication adherence-related concerns and patients were satisfied with the services provided.
View article: The immune cell landscape in kidneys of lupus nephritis patients
The immune cell landscape in kidneys of lupus nephritis patients Open
Lupus nephritis is a potentially fatal autoimmune disease, whose current treatment is ineffective and often toxic. To gain insights into disease mechanisms, we analyzed kidney samples from lupus nephritis patients and healthy controls usin…
View article: Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D<sub>3</sub> on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D<sub>3</sub> on the Interferon Signature in Patients With Systemic Lupus Erythematosus Open
Objective Vitamin D modulates the immune response and blocks induction of an interferon (IFN) signature by systemic lupus erythematosus (SLE) sera. This study was undertaken to investigate the effects of vitamin D supplementation on the IF…
View article: Marked hyperferritinemia does not predict for HLH in the adult population
Marked hyperferritinemia does not predict for HLH in the adult population Open
Key Points Highly elevated ferritin is not specific for hemophagocytic lymphohistiocytosis in adults. Marked hyperferritinemia in adults most often occurs in the setting of renal failure, hepatocellular injury, infection, or malignancy.